CG
BHVN

Cutler Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cutler Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-600
Closed -$1K – 5699
2022
Q3 		$1K Sell
600
-5,700
-90% -$845K ﹤0.01% 4822
2022
Q2 		$49K Sell
6,300
-13,000
-67% -$1.66M ﹤0.01% 1965
2022
Q1 		$70K Buy
19,300
+4,600
+31% +$574K ﹤0.01% 1979
2021
Q4 		$260K Buy
14,700
+14,500
+7,250% +$1.84M 0.01% 1126
2021
Q3 		$13K Hold
200
– – ﹤0.01% 3739
2021
Q2 		$5K Sell
200
-5,100
-96% -$414K ﹤0.01% 4532
2021
Q1 		$2K Sell
5,300
-13,900
-72% -$1.12M ﹤0.01% 5100
2020
Q4 		$204K Sell
19,200
-3,500
-15% -$297K 0.01% 1073
2020
Q3 		$65K Sell
22,700
-7,000
-24% -$459K ﹤0.01% 1623
2020
Q2 		$370K Buy
+29,700
New +$1.58M 0.02% 588
2020
Q1 		– Sell
-6,100
Closed -$40K – 5085
2019
Q4 		$40K Sell
6,100
-3,600
-37% -$178K ﹤0.01% 1788
2019
Q3 		$25K Buy
9,700
+6,300
+185% +$266K ﹤0.01% 2045
2019
Q2 		$10K Buy
+3,400
New +$192K ﹤0.01% 2715
2018
Q2 		– Sell
-8,300
Closed -$8K – 5417
2018
Q1 		$8K Buy
+8,300
New +$248K ﹤0.01% 3015

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Cutler Group's BHVN Position: Q4 2022 in Review

Cutler Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,300 shares — an estimated $196K sold.

Cutler Group first reported a position in BHVN in Q1 2018 and held it in 16 quarters. The position peaked at $1.32M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Cutler Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 1,300 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $196K.
  • Cutler Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 16 quarters.
  • Cutler Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.32M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.